pp-184 Capsules
Dossier type
CTD
Dossier status
Under development
Country of origin
Taiwan
GMP approvals
Taiwan
Comments
Indication: Metastatic pancreatic ductal adenocarcinoma (mPDAC) — first-line
Clinical stage: Phase 3 — IND accepted December 2025; Phase 3 initiation imminent
Modality: Small molecule (ubiquinone / terpenoid derivative)
Mechanism / Target: Ubiquinone analogue; inhibits AMPK–mTOR pathway and KRAS-driven oncogenic signalling; reduces aerobic glycolysis and induces apoptosis in KRAS-mutated tumour cells
Route / form: Oral capsule
Differentiation: First-in-class ubiquinone derivative targeting KRAS-driven pancreatic cancer;
Manufacturer #39325
Listed biopharmaceutical company focused on discovery and development of innovative Rx therapeutics for oncology and serious diseases, alongside evidence-based OTC health supplement products. Advances proprietary drug candidates through global clinical development with engagement in major regulated markets. Operates within a leading biomedical science park environment.
None